Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activity and safety of larotrectinib in adult patients with TRK fusion cancer: An expanded data set
    Meeting Abstract

    Drilon, A. E.; Farago, A. F.; Tan, D. S. W.; Kummar, S.; McDermott, R. S.; Berlin, J.; Patel, J. D.; Brose, M. S.; Leyvraz, S.; Tahara, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models
    Meeting Abstract

    Drilon, A. E.; Zhai, D. Y.; Rogers, E.; Deng, W.; Zhang, X.; Ung, J.; Lee, D.; Rodon, L.; Graber, A.; Zimmerman, Z. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pilot program of remote monitoring for high-risk patients on antineoplastic treatment
    Meeting Abstract

    Daly, R. M.; Kuperman, G.; Zervoudakis, A.; Ro, A.; Roy, A.; Baldwin, A.; Salvaggio, R.; Holland, J. C.; Chow, K.; Lauria, T.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis
    Meeting Abstract

    Bolton, K. L.; Moukarzel, L. A.; Ptashkin, R.; Gao, T.; Patel, M.; Caltabellotta, N.; Braunstein, L. Z.; Aghajanian, C.; Hyman, D. M.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Success and failure of additional immunosuppressants in steroid-refractory pneumonitis related to immune checkpoint blockade
    Meeting Abstract

    Beattie, J.; Fuentes, P.; Rizvi, H.; Luo, J.; Schoenfeld, A. J.; Postow, M. A.; Callahan, M. K.; Warner, A. B.; Chawla, M.; Hellmann, M. D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer
    Meeting Abstract

    Arbour, K. C.; Rizvi, H.; Plodkowski, A. J.; Halpenny, D.; Hellmann, M. D.; Heller, G.; Knezevic, A.; Yu, H. A.; Ladanyi, M.; Kris, M. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status
    Meeting Abstract

    Alessi, J. V. M.; Ricciuti, B.; Aguilar, E. J.; Hong, F.; Wei, Z.; Nishino, M.; Plodkowski, A. J.; Sawan, P.; Luo, J.; Rizvi, H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • COVID-19 in patients with lung cancers in New York City
    Meeting Abstract

    Luo, J.; Rizvi, H.; Preeshagul, I. R.; Egger, J. V.; Hoyos, D.; Bandlamudi, C.; Donoghue, M. T. A.; Łuksza, M.; Greenbaum, B. D.; Wolchok, J. D.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Overcoming immune resistance with rationally designed combination immunotherapy
    Meeting Abstract

    Zappasodi, R.; Budhu, S.; Sirard, C.; Qi, J.; Liu, C.; Li, Y.; Senbabaoglu, Y.; Manne, S.; Gasmi, B.; Zhong, H.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
    Meeting Abstract

    Yu, H. A.; Baik, C. S.; Gold, K.; Hayashi, H.; Johnson, M.; Koczywas, M.; Murakami, H.; Nishio, M.; Steuer, C.; Su, W. C.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save